Carol Brosgart

11.1k total citations · 3 hit papers
89 papers, 7.8k citations indexed

About

Carol Brosgart is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Carol Brosgart has authored 89 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Epidemiology, 73 papers in Hepatology and 38 papers in Infectious Diseases. Recurrent topics in Carol Brosgart's work include Hepatitis B Virus Studies (75 papers), Hepatitis C virus research (73 papers) and Liver Disease Diagnosis and Treatment (35 papers). Carol Brosgart is often cited by papers focused on Hepatitis B Virus Studies (75 papers), Hepatitis C virus research (73 papers) and Liver Disease Diagnosis and Treatment (35 papers). Carol Brosgart collaborates with scholars based in United States, France and Canada. Carol Brosgart's co-authors include Shelly Xiong, Patrick Marcellin, Seng Gee Lim, Zachary Goodman, John Fry, Stephanos J. Hadziyannis, Michael Wulfsohn, E. Jenny Heathcote, G. Kitis and Ting‐Tsung Chang and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

Carol Brosgart

85 papers receiving 7.5k citations

Hit Papers

Adefovir Dipivoxil for the Treatment of Hepatitis B e Ant... 2003 2026 2010 2018 2003 2003 2006 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B
    2003 1.0k citations Patrick Marcellin, Ting‐Tsung Chang et al. New England Journal of Medicine profile →
  2. Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Negative Chronic Hepatitis B
    2003 749 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. New England Journal of Medicine profile →
  3. Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years
    2006 703 citations Stephanos J. Hadziyannis, Nicolaos C. Tassopoulos et al. Gastroenterology profile →

Peers

Carol Brosgart
Yves Benhamou France
Ting‐Tsung Chang Taiwan
Edward Tam United States
Juan Macı́as Spain
Stefan Mauss Germany
Javier García‐Samaniego Spain
Behzad Hajarizadeh Australia
M J Alter United States
Diana M. Brainard United States
Anne Cross United States
Yves Benhamou France
Carol Brosgart
Citations per year, relative to Carol Brosgart Carol Brosgart (= 1×) peers Yves Benhamou

Countries citing papers authored by Carol Brosgart

Since Specialization
Citations

This map shows the geographic impact of Carol Brosgart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol Brosgart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol Brosgart more than expected).

Fields of papers citing papers by Carol Brosgart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol Brosgart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol Brosgart. The network helps show where Carol Brosgart may publish in the future.

Co-authorship network of co-authors of Carol Brosgart

This figure shows the co-authorship network connecting the top 25 collaborators of Carol Brosgart. A scholar is included among the top collaborators of Carol Brosgart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol Brosgart. Carol Brosgart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gish, Robert G., et al.. (2023). Test All for Hepatitis B Virus. Clinics in Liver Disease. 27(4). 997–1022. 2 indexed citations
2.
Wong, Robert J., Carol Brosgart, Mark Chen, et al.. (2021). An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign‐Born Persons Living in the United States. Hepatology. 74(2). 607–626. 93 indexed citations
3.
Perrillo, Robert P., Hie-Won Hann, Eugene R. Schiff, et al.. (2011). Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatology International. 5(2). 654–663. 11 indexed citations
4.
Kowdley, Kris V., et al.. (2011). Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 56(2). 422–433. 310 indexed citations
5.
Kim, W. Ray, Norah A. Terrault, Rachel Pedersen, et al.. (2009). Trends in Waiting List Registration for Liver Transplantation for Viral Hepatitis in the United States. Gastroenterology. 137(5). 1680–1686. 106 indexed citations
6.
Sung, Joseph J.�Y., Stefan Zeuzem, E. Jenny Heathcote, et al.. (2008). Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. Journal of Hepatology. 48(5). 728–735. 117 indexed citations
7.
Lütgehetmann, Marc, Karsten Wursthorn, Peter Buggisch, et al.. (2006). 508 48 Weeks of adefovir mono therapy following 48 weeks of combination therapy with peginterferon alpha-2b and adefovir leads to additional biochemical and virological improvement. Journal of Hepatology. 44. S189–S189. 1 indexed citations
8.
Hadziyannis, Stephanos J., Nicolaos C. Tassopoulos, E. Jenny Heathcote, et al.. (2006). Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 Years. Gastroenterology. 131(6). 1743–1751. 703 indexed citations breakdown →
9.
Hadziyannis, Stephanos J., Nicolaos C. Tassopoulos, E. Jenny Heathcote, et al.. (2005). Long-Term Therapy with Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B. New England Journal of Medicine. 352(26). 2673–2681. 407 indexed citations
10.
Hadziyannis, Stephanos J., N.C. Tassopoulos, E. Jenny Heathcote, et al.. (2005). Long-term (3-year) Therapy with Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen Negative Chronic Hepatitis B. New England Journal of Medicine. 352(26). 9 indexed citations
11.
Izzedine, Hassane, Jean‐Sébastien Hulot, Vincent Launay‐Vacher, et al.. (2004). Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney International. 66(3). 1153–1158. 127 indexed citations
12.
Peters, Marion G., Hie‐Won Hann, Paul Martin, et al.. (2003). Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).. Gastroenterology. 126(1). 91–101. 440 indexed citations
13.
Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2003). Adefovir Dipivoxil for the Treatment of Hepatitis B e Antigen–Positive Chronic Hepatitis B. New England Journal of Medicine. 348(9). 808–816. 1010 indexed citations breakdown →
14.
15.
Yang, Huiling, Christopher Westland, William E. Delaney, et al.. (2002). Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology. 36(2). 464–473. 132 indexed citations
16.
Falloon, Judith, Mounir Ait‐Khaled, Deborah A. Thomas, et al.. (2002). HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients. AIDS. 16(3). 387–396. 31 indexed citations
17.
Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2001). GS-98-437 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for the treatment of patients with HBeAg+ chronic hepatitis B infection: 48 week results.. Hepatology. 34(4). 13 indexed citations
18.
Brosgart, Carol, et al.. (1999). Clinical Experience and Choice of Drug Therapy for Human Immunodeficiency Virus Disease. Clinical Infectious Diseases. 28(1). 14–22. 37 indexed citations
19.
Jacobson, Mark Z., D M Yajko, Donald W. Northfelt, et al.. (1993). Randomized, Placebo-Controlled Trial of Rifampin, Ethambutol, and Ciprofloxacin for AIDS Patients with Disseminated Mycobacterium avium Complex Infection. The Journal of Infectious Diseases. 168(1). 112–119. 44 indexed citations
20.
Abrams, Donald I., et al.. (1993). Clofazimine as Prophylaxis for Disseminated Mycobacterium avium Complex Infection in AIDS. The Journal of Infectious Diseases. 167(6). 1459–1463. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yves Benhamou Breakdown of academic impact, for papers by Ting‐Tsung Chang Breakdown of academic impact, for papers by Edward Tam Breakdown of academic impact, for papers by Juan Macı́as Breakdown of academic impact, for papers by Stefan Mauss Breakdown of academic impact, for papers by Javier García‐Samaniego Breakdown of academic impact, for papers by Behzad Hajarizadeh Breakdown of academic impact, for papers by M J Alter Breakdown of academic impact, for papers by Diana M. Brainard Breakdown of academic impact, for papers by Anne Cross
Rankless by CCL
2026